Biocon Biologics Limited is a global biosimilars company focused on developing, manufacturing and commercializing affordable biologic therapies—such as insulin and monoclonal antibodies—to expand patient access worldwide. Combining large-scale manufacturing capabilities with targeted R&D and strategic partnerships, the company aims to accelerate commercialization across regulated and emerging markets while driving cost-effective alternatives to branded biologics.
EN